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Current therapeutics and prophylactics for malaria are under se-
vere challenge as a result of the rapid emergence of drug-resistant
parasites. The human malaria parasite Plasmodium falciparum
expresses two neutral aminopeptidases, PfA-M1 and PfA-M17,
which function in regulating the intracellular pool of amino acids
required for growth and development inside the red blood cell.
These enzymes are essential for parasite viability and are validated
therapeutic targets. We previously reported the x-ray crystal struc-
ture of the monomeric PfA-M1 and proposed a mechanism for sub-
strate entry and free amino acid release from the active site. Here,
we present the x-ray crystal structure of the hexameric leucine ami-
nopeptidase, PfA-M17, alone and in complex with two inhibitors
with antimalarial activity. The six active sites of the PfA-M17 hex-
amer are arranged in a disc-like fashion so that they are orientated
inwards to form a central catalytic cavity; flexible loops that sit at
each of the six entrances to the catalytic cavern function to regu-
late substrate access. In stark contrast to PfA-M1, PfA-M17 has a
narrow and hydrophobic primary specificity pocket which accounts
for its highly restricted substrate specificity. We also explicate the
essential roles for the metal-binding centers in these enzymes (two
in PfA-M17 and one in PfA-M1) in both substrate and drug binding.
Our detailed understanding of the PfA-M1 and PfA-M17 active
sites now permits a rational approach in the development of a un-
ique class of two-target and/or combination antimalarial therapy.
drug design ∣ malaria ∣ protease ∣ structural biology ∣
neutral aminopeptidases
An estimated 1–2 million people die each year as a conse-quence of infection with apicomplexan parasites of the genus
Plasmodium (1). The widespread appearance of drug-resistant
malaria parasites, even to newly developed second and third
generation therapeutics such artemisinin and its derivatives,
makes the development of unique antimalarial drug treatments
all the more urgent (2).
Neutral aminopeptidases are ubiquitous in mammalian cells
and are generally involved in protein processing by clipping
N-terminal amino acids, such as the trimming of peptides to
achieve optimal binding to Major Histocompatibility Complex
class I molecules (3), or in the final stages of protein degradation.
Malaria parasites express two such enzymes, a 122 kDa M1-
family alanyl aminopeptidase and a 67.8 kDa M17-family leucyl
aminopeptidase, termed PfA-M1 (MAL13P1.56, plasmodb.org)
and PfA-M17 (Pf14_0439, plasmodb.org), respectively (4–8).
The concerted functions of these enzymes are essential for para-
site viability as targeted gene-knock-outs have been unsuccessful
(4, 7, 8). Both enzymes function in the blood stage of the infection
and are responsible for regulating the intracellular amino acid
pool within malaria cells, most likely by releasing amino acids
from host-derived haemoglobin. In addition to providing essen-
tial nutrients for parasite growth and development, digestion of
haemoglobin is important for maintaining the osmotic integrity of
infected red blood cells (9). PfA-M1 and PfA-M17 are validated
therapeutic targets for a unique class of antimalarial drugs.
Blocking the activity of these aminopeptidases by dipeptide
analogs prevents growth of P. falciparum in culture and kills
P. c. chabaudi malaria in vivo (4–7, 10).
Both PfA-M17 and PfA-M1 are able to efficiently cleave
N-terminal amino acids from peptide substrates; however their
specificities differ dramatically. PfA-M1 exhibits a far broader
substrate specificity than PfA-M17 and rapidly hydrolyses sub-
strates containing Leu, Ala, Arg, and Lys, but can also cleave sub-
strates containing Phe, Tyr, Ser, and Asn (but not Glu or Asp)
(4, 11, 12). In contrast, PfA-M17 possesses a severely restricted
specificity for N terminally exposed leucine; alanine substrates
are cleaved relatively poorly (∼850 fold lower than Leu) and sub-
strates containing an Arg, Val, Pro, Gly, Ile, Glu, or Asp in the P1
position are not cleaved at all (7). These insights into to the dif-
fering specificities of the two enzymes have already permitted de-
velopment of an P1-Arg-specific enzymatic assay for detecting the
activity of PfA-M1 in malaria cytosolic extracts (4).
The two enzymes also have distinct differences in the arrange-
ment of divalent metal cations in their active site. PfA-M1 binds a
single, tightly-bound Zn2þ metal ion whereas PfA-M17 contains
two metal-binding sites, a readily exchangeable site (site 1) and a
tight-binding site (site 2) (13). Whereas PfA-M17 retains residual
catalytic activity when the metal ion from site 1 is removed, the
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removal of metal ions from both sites results in an inactive apoen-
zyme that cannot be reactivated by addition of divalent metal ca-
tions (13). However, the divalent metal cation binding at site 1 of
PfA-M17 can be functionally exchanged for other metal cations,
the enzyme displaying a preference in the order Zn2þ > Mn2þ >
Co2þ > Mg2þ (13). The type of metal cation in the active site of
these enzymes can therefore influence the catalytic efficiency
against peptide substrates as well as the binding of inhibitors. To-
gether, these data highlight the importance of understanding the
catalytic role of metal atoms for the future optimization of lead
inhibitory compounds.
In this study we present the structure of the hexameric
PfA-M17 enzyme, with one (PfA-M17 Zn2þ) and two (PfA-
M17 Zn2þZn2þ) metal ions bound in the active site. We also have
determined the structure of PfA-M17 in the complex with the
inhibitors bestatin (PfA-M17-BES) and phosphinic dipeptide
analogue hPheP½CH2Phe (termed compound 4, Co4; PfA-
M17-Co4). We compare and contrast these data with our pre-
viously determined structure of PfA-M1 in complex with the
same inhibitors and reveal dramatic differences in the manner
in which the two enzymes receive, bind, and cleave N-terminal
amino acid substrates. These studies will lead a rational approach
in the development of inhibitors that have dual and selective ac-
tivity for PfA-M17 and PfA-M1. Such reagents will permit key
insights into the precise role of each enzyme in the parasite life-
cycle and guide the structure-based design of unique classes of
antimalarial therapeutics.
Results
The Overall Structure of PfA-M17. The 2.0 Å x-ray crystal structure
of the PfA-M17 Zn2þ aminopeptidase revealed two hexamers in
the asymmetric unit (SI Text Table S1). Each PfA-M17 monomer
contains an N-terminal regulatory domain and a C-terminal cat-
alytic domain that together adopt the leucine aminopeptidase
(LAP) fold (14). Further, the general hexameric arrangement
of monomers is consistent with the physiological assembly de-
scribed for PfA-M17 and other LAP family members (14–16).
Structural comparison (17) of the twelve monomers reveals only
minor differences are apparent in loop regions, particularly in the
N-terminal domain (average r:m:s:d ¼ 0.3 Å over 555 Cα atoms).
Unless indicated otherwise we refer to monomer A (Fig. 1A) and/
or the functional hexamer (Fig. 1B, C) formed by molecules A–F.
Numbering is for PfA-M17.
For each monomer, the N-terminal domain (85-276) comprises
a central six-stranded β-sheet and three α-helices (Fig. 1A). A
∼30 Å helix (277-300) connects the N-terminal domain with
the C-terminal catalytic domain (301-605) through the center
of the molecule (Fig. 1A).
The catalytic domain comprises a central eight-stranded
β-sheet flanked on both sides by nine α-helices and with a two-
stranded β-sheet capping one end (Fig. 1A). The active site is
entirely contained within the catalytic domain (Fig. 1A) and is
located near the edge of the central β-sheet. The active site cleft
measures 18 Å by 18 Å and contains a cluster of negatively
charged residues that function to coordinate metal cations.
Whereas the crystal trials were established on monomeric ma-
terial, the structure of PfA-M17 revealed the classic LAP hex-
americ assembly within the asymmetric unit and, in keeping
with other enzymes in this superfamily, we suggest this represents
the biologically relevant active form.
The six active sites are located in the interior of the molecule,
where they line a disk-shaped cavity of diameter of ∼35 Å and
height ∼15 Å. Access to the cavity occurs by channels formed
by the N-terminal domains of each monomer. Most importantly,
a ∼20 Å loop between helix 3 and strand 6 which is partially dis-
ordered in 10 of the 12 monomers, sits at the entrance to the cat-
alytic cavity (Fig. 1A, D). The complete loop is visible in electron
density in chains C and I where it occludes the entrance to the
enzyme interior (Fig 1D). We suggest that flexibility of this loop
may regulate substrate entrance and product exit from the buried
aminopeptidase active sites (Fig. 1D).
Binding of Metal Ions in the Active Site of PfA-M17. The LAP struc-
tures described to date contain two metal ions in the active site.
Biophysical studies on this enzyme family reveal that the first
site is readily exchangeable and is thus termed the “loose” or
regulatory site 1 (18). In contrast, the second metal ion is “tight-
binding” and is known as the catalytic site 2 (18). Metal replace-
ment studies on PfA-M17 show that the enzyme retains activity
when only the tight-binding catalytic site 2 is occupied with a met-
al ion; removal of both metal ions lead to complete and irrevers-
ible inactivity (7, 13). Consistent with these ideas, in the presence
of increasing concentrations of EDTA, loss of M17 activity fol-
lows a biphasic pattern as each metal ion is sequentially chelated
(13) (SI Text Fig. S1). In contrast, studies on PfA-M1 reveal that
this enzyme contains a single, essential, tightly-bound metal ion.
Accordingly, increasing concentrations of EDTA eventually re-
move this metal ion in a monophasic manner, resulting in a sud-
den and irreversible loss of enzyme activity (SI Text Fig. S1).
Interestingly, the structure of PfA-M17 Zn2þ revealed that
only the catalytic site 2 was occupied by a zinc ion and no electron
density was visible for the site 1 metal ion. It is therefore sug-
gested that the loosely bound metal site was lost during purifica-
tion. High B-factors were also noted for the single zinc ion—
suggesting local disorder of this atom.
In PfA-M17 Zn2þ, the site 2 zinc is coordinated by Lys374,
Asp379, Asp399, and Glu461 and two water molecules, creating a
hexameric coordination of this ion (SI Text Fig. S2). For this,
and all the other structures we report, we also observed strong
planar density consistent with the presence of a carbonate ion
in the PfA-M17 active site (previously noted in all other LAP
crystal structures (19)) which forms hydrogen bonds to residues
Lys374, Ala460, Gly462, Arg463, and Leu487 (SI Text Fig. S2). The
carbonate ion has been proposed to act as a general base, accept-
ing the proton and activating a (nucleophilic) metal-bridging
water (19).
To understand the position and role of the metal atom in the
site 1 position, we conducted soaking experiments on crystals and
determined the 2.4 Å structure of PfA-M17 Zn2þZn2þ (SI Text
Table S1). These data revealed a di-zinc center in the active site
with strong Fo-Fc density for both zinc positions. The two metal
ions are 2.9 Å apart (SI Text Fig. S2), however, in comparison to
PfA-M17 Zn2þ, the position of the modeled and refined Zn in
catalytic site 2 is slightly shifted by ∼0.4 Å. In PfA-M17 Zn2þ
Zn2þ, the catalytic site 1 Zn2þ is coordinated by Asp379, Asp459,
and Glu461, whereas coordination of the catalytic site 2 Zn is
similar to PfA-M17 Zn2þ (SI Text Fig. S2).
Our biochemical studies suggest that the ability of PfA-M17 to
rapidly gain or lose a divalent cation, most likely at the regulatory
site 1, may represent an important mechanism of regulation of
catalytic activity not only for the binding of substrates but also
inhibitors (13). Consistent with this idea, we found that in the
absence of environmental metal, no metal ion was observed at
the catalytic site 1 position (SI Text Fig. S2). Both metal atoms
are also visible in electron density in the inhibitor-bound forms
(discussed in the next section).
Interaction of the Antimalarial Inhibitors Bestatin and Co4 with
PfA-M17 and Comparison with PfA-M1. Two inhibitors of PfA-M1
and PfA-M17 enzyme have been well characterized, bestatin and
compound 4 (Co4; phosphinic dipeptide analog) (5). We deter-
mined each inhibitor/enzyme complex structures to 2.0 and 2.6 Å
resolution, respectively (SI Text Table S1). The bestatin-bound
(PfA-M17-BES) and Co4-bound (PfA-M17-Co4) enzyme struc-
tures were obtained from crystallization experiments conducted
in the presence of Mg2þ and Zn2þ, respectively.
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The electron density of the modeled ligands within the active
site was well defined (Fig. 2). Both ligands form extensive inter-
actions with the active site and the carbonate ion, however, the
presence of the inhibitor did not result in any major conforma-
tional change or movement of active site side-chains (Overall
r.m.s.d. of representative monomer chain was 0.2 Å for PfA-
M17-BES and 0.3 Å for PfA-M17-Co4 over 522 cα atoms).
The PfA-M17-BES structure revealed pentavalent coordina-
tion of the site 1 Mg2þ ion (Fig. 2A). The bestatin molecule bur-
ied a surface area of 44.2 Å2 and fitted neatly into each active site
with the hydroxyl group (O2) and central nitrogen (N2) coordi-
nating the active site metals (Fig. 2A). Bestatin forms hydrogen
bonds with 12 residues in the active site (predominantly with
metal coordinating residues, SI Text Table S2) and in addition
makes eight van der Waal interactions with other residues lining
the pocket. The P1 Phe side-chain of bestatin is packed into the
S1 pocket and forms interactions with the hydrophobic residues
Met392, Met396, Phe398, Gly489, and Ala577. The P1′ position
makes only two interactions with Asn457 and Ile547.
The PfA-M17-Co4 structure revealed that the buried surface
area of the Co4 inhibitor (195.1 Å2) was significantly larger than
that occluded by bestatin. Strong Fo-Fc density was observed for
both zinc ions in the active site. As a consequence of its central
phosphate group, and in contrast to bestatin, Co4 is able to co-
ordinate the catalytic site 1 Zn2þ in a hexavalent fashion (Fig. 2B).
Indeed, the central phosphate group of the ligand dominates
interactions with the active site metals with both phosphoryl
oxygens (O3∕O4) interacting with the catalytic site 1Zn2þ,
whereas the catalytic site 2 Zn2þ is bound by the O4 atom as well
as Co4 N atom. The differences in how Co4 and bestatin coor-
dinate the site 1 Zn2þ (Fig. 2 and SI Text Fig. S3) may explain the
linear inhibitory kinetics exhibited by Co4 versus the slow/tight-
binding kinetics exhibited by bestatin (5, 7).
Aside from the differences in coordination of metal atoms,
Co4 and bestatin interact with the active site in a similar fashion
(Fig. 2), although Co4 forms only eight hydrogen bonds and one
extra van der Waal interaction (at the P1 position with Leu492; SI
Text Table S2).
Both bestatin and Co4 are far superior inhibitors of PfA-M17
than PfA-M1 (the Ki for bestatin is 25 and 478 and for Co4 are 13
and 79 nM, respectively, SI Text Table S4). Consistent with this
observation, a comparison of the four inhibitor-bound structures
reveal that each inhibitor makes far more extensive interactions
with the PfA-M17 active site than with PfA-M1 (SI Text
Table S4). Furthermore, in contrast to PfA-M17, in PfA-M1 both
inhibitors coordinate the single active site Zn2þ atom (equivalent
to the site 1 metal in PfA-M17; SI Text Fig. S3) in the same (pen-
tavalent) fashion. We also compared the inhibitor conformation
in the active site of PfA-M17 with that seen in PfA-M1 (4). These
data reveal that the general conformation of the inhibitor scaffold
in both enzymes is quite similar, however, variation in the side-
chain rotamers of the P1 and P1′ positions are observed (SI
Text Fig. S3).
Structural Basis for the Differing Substrate Specificity of PfA-M1 and
PfA-M17.Although the two Plasmodium neutral aminopeptidases
Fig. 1. The structure of PfA-M17. (A) Diagram of the unbound PfA-M17monomer colored by domain: N-terminal domain (Green), helical region linking the
two domains (Yellow) and C-terminal catalytic domain (Red). The partially disordered loop that sits at the entrance to the active site chamber in the hexameric
assembly is shown in magenta. The single zinc atom present in the site 2 position (the site 1 position is unoccupied in this structure, PfA-M17 Zn2þ) is shown as a
black sphere and is labeled. (B, C) Cartoon diagrams of the biologically functional PfA-M17 hexamer colored by chain: A (Green); B (Blue); C (Red); D (Yellow)
E (Orange) F (Brown). The six active sites line an interior cavity. (D) The molecular surface of PfA-M17 Zn2þ by chain (as colored in (B, C). The active site zinc and
carbonate of chain B are visible (Purple spheres). Chains C & D are occluded in this view. The position of the loop (with the molecular surface omitted) in chain B
that sits at the entrance to the catalytic cavity is shown by yellow coil (residues 246-265). This region is disordered in the other chains.
McGowan et al. PNAS ∣ February 9, 2010 ∣ vol. 107 ∣ no. 6 ∣ 2451
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exhibit some overlap in the amino acids that can be accommo-
dated into their active sites (in particular Leu and Phe (4, 7);
SI Text Table S3), each protease has distinct substrate profiles that
can be explained by key features within their active sites.
The PfA-M17 S1 pocket that interacts with the substrate P1
residue is a narrow and substantially hydrophobic pocket lined
at the entrance by Met392, Met396, Phe398, Thr486, Gly489, Leu492,
and Phe583 (Fig. 3A–C). In both inhibitor-bound structures the P1
Phe-like moieties are tightly packed into this S1 pocket, in partic-
ular stacking against the aromatic ring of Phe398 (Fig. 3A–C). The
hydrophobic nature of this narrow pocket underlies the restricted
substrate profile of PfA-M17, and explains the inability of this
enzyme to cleave peptides/proteins after polar residues such as
Arg, Glu, or Asp residues. Indeed, inspection of PfA-M17 struc-
ture reveals no suitable polar hydrogen-bonding partners at the
base of the S1 pocket that could interact with a charged P1 side-
chain (Fig. 3C). With respect to smaller P1 residues, we suggest
that amino acids such as Ala and Gly would fail to reach far
enough into the S1 pocket to bind properly.
In contrast, the molecular basis for PfA-M1 substrate pro-
miscuity is apparent upon inspection of its S1 pocket which is
much larger than that of PfA-M17 (Fig. 3D–F). Comparison
of inhibitor-bound and unbound PfA-M1 structures also revealed
that the side-chain of Met1034 is able to move upon inhibitor bind-
ing; this residue may provide further flexibility in regards to the
shape of the S1 pocket. Most notably, whereas the entrance to the
specificity pocket is lined by hydrophobic residues (Val459, Tyr575,
and Met1034), a polar glutamic acid (Glu572) residue is located at
the base of the pocket where it would be available to form an
ionic interaction with the side-chain of a P1 Arg (Fig. 3F).
Discussion
Malaria parasites utilize proteases inmany aspects of their intraer-
ythrocytic cycle, including employing the serine protease subtilisin
1 and a dipeptidyl peptidase 3 to effect egress from the cell (20).
Numerous proteases also degrade host haemoglobin in the diges-
tive food vacuole as intraerythrocytic parasites (21). Although
initial studies suggested that these digestive vacuole enzymes
might represent attractive drug targets, additional gene targeting
Fig. 2. Stereo diagram of inhibitors binding to active site of PfA-M17.
(A) 2.0 Å PfA-M17-BES and (B) 2.6 Å PfA-M17-Co4 active site showing inhi-
bitors bound in the active site. Inhibitors (BES/Co4) are colored in magenta.
Carbon atoms of residues are colored green. Zinc is shown as black sphere;
Magnesium as yellow sphere and water molecules are light-blue spheres. Hy-
drogen and metallo-bonds are indicated (dashed lines). Electron density is a
composite omit map showing averaged density of 12 protein chains con-
toured at 3.0 σ calculated by using a model containing only PfA-M17 atoms
(no metal, ligand, or water was included in calculation).
Fig. 3. Comparison of the active site cleft and S1 binding pockets of
PfA-M17 and PfA-M1. (A), (B) CCP4MG electrostatic potential surface of
the active sites of (A) PfA-M17-BES and (B) PfA-M17-Co4. (C) Cartoon of
PfA-M17-Co4 showing the residues lining the S1 pocket (labeled and in stick).
(D), (E) show a CCP4MG electrostatic potential surface of the active site of
PfA-M1-BES (D) and PfA-M1-Co4 (E). (F) shows a cartoon depicting the resi-
dues lining the S1 pocket (labeled and in stick) for PfA-M1-Co4. Throughout
this figure, electrostatic surfaces are color-coded according to electrostatic
potential calculated by the Poisson-Boltzmann solver within CCPMG. Metal
ions are shown as black spheres. The carbonate ion in PfA-M17 (A), (B) is
shown as ball and stick (Black). The S1 pocket of active sites are indicated (*).
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and inhibitory studies have now revealed that this is not the case
with many of these enzymes having redundant functions (9).
In malaria parasites we, and others, have identified two essen-
tial netural aminopeptidases, PfA-M1 and PfA-M17, each of
which is encoded by a single-copy gene. Gene targeting and in
vivo animal experiments have demonstrated that parasites are
unable to tolerate inhibition or inactivation of either enzyme,
validating these molecules as therapeutic targets (4–7, 10).
Whereas the precise functions of PfA-M1 and PfA-M17 are
still speculative it is suggested that these enzymes function in
the final stages of haemoglobin digestion and degrade the dipep-
tides produced by the action of various enzymes within the para-
site’s acidic digestive vacuole (4, 5, 7, 8). This process is essential
for the provision of free amino acids for parasite protein synth-
esis. However, where in the malaria parasite and how these en-
zymes may perform this process (or any other function) is under
debate largely because of reports that present conflicting data de-
picting the cellular location of the PfA-M1 enzyme (22, 23). The
consensus is that the PfA-M17 is located within the cytosol of the
parasite. However, while we (4) and others (11, 12) have also
located the PfA-M1 within the cytosolic compartment by immu-
nocytochemistry, Dalal and Klemba (2007), using immuno-
cytochemistry, light microscopy and YFP-tagging, observed the
enzyme in the acidic digestive vacuole and nucleus (8).
Our biochemical data show that the two enzymes exhibit op-
timal activity at neutral pH and little or no activity at the resident
pH of the digestive vacuole (pH 5.2) suggesting that their primary
function is cytosolic. By extension, we had proposed that small
peptides and dipeptides derived from haemoglobin digestion
were transported from the digestive vacuole to the cytosol for
final break-down by these enzymes to free amino acids (4, 22).
Consistent with this idea, our studies reveal that both enzymes
contain buried active sites that would most likely be inaccessible
to all but small peptides. However, our structural data reveal that
such peptides enter the two enzymes in remarkably different
ways. The present study reveals that the six active sites of the
PfA-M17 hexamer are arranged in a disc-like fashion so that they
are orientated inwards to form a central catalytic cavity. Whereas
this large space itself does not present any obstacle to substrate
ingress and amino acid egress, it suggests that flexible loops sit at
each of the six entrances to the catalytic cavern and function to
regulate peptide access (Fig. 1D). In contrast, our previous anal-
ysis of the three-dimensional structure of the PfA-M1 showed
how four distinct domains within the protein combine to form
two channels that connect the exterior environment to the deeply
buried active site. The configuration of these channels led us to
propose that peptide substrates reach the PfA-M1 active site
through a large (13 Å in diameter and 30 Å in length) entrance
tunnel and that amino acids are released through the smaller
opening (8 Å) located on the opposite side of the enzyme (4).
Taken together, however, both strategies would effectively limit
the size of substrates that could access the active site, thus pre-
venting unwanted and potentially deleterious PfA-M1 and
PfA-M17 activity against larger protein substrates.
A number of interesting and important questions remain. Most
notably, given the broad specificity of the PfA-M1, including its
ability to efficiently cleave Leu and Phe, it is unclear why this
enzyme would need to function alongside the Leu-specific PfA-
M17. One suggestion is that the role of PfA-M17 may be linked
to the inability of malaria parasites to synthesize isoleucine.
Whereas Ile is one of the most abundant amino acids in malaria
proteins it is nevertheless absent from host haemoglobin and
therefore the parasite must source this amino acid from the ex-
tracellular milieu (24). The parasite achieves this by exchanging
intracellular leucine by a two-step process that involves an ATP-
independent transporter capable of exchanging intracellular leu-
cine for isoleucine, followed by the ATP-dependent storage or
accumulation of isoleucine within the parasite (25). These data
lead us to speculate that the essential nature of the Leu-specific
PfA-M17 may relate to the requirement for an ample supply of
free leucine within the malaria cytosol to exchange for isoleucine.
The structural information obtained in this study, together
with our previously published work on PfA-M1, will facilitate
a rational approach in the design of unique PfA-M1 and PfA-
M17 inhibitors and, furthermore will readily permit fragment-
based screening and crystallographic studies on new leads. It is
also notable that our studies reveal that PfA-M17 is able to exist
with only a single metal ion bound to catalytic site 2, and that
inhibitors, and perhaps substrates, themselves play an important
role in the capture and/or coordination of the site 1 (loose) di-
valent cation. This feature, together with inhibitor interactions
with the catalytic site 2 cation and other key differences between
the active sites may be utilized for the development of specific
compounds that target PfA-M17 but are unable to inhibit PfA-
M1, and vice versa. Such reagents will help identify the relative
efficacy (in terms of killing parasites) of inhibiting each enzyme
alone and in combination as well as permitting a greater under-
standing of how malaria parasites acquire nutrients from inside
and outside the erythrocyte. Together, such biological insights will
be imperative for driving the overall drug development strategy
for this enzyme system towards either a conventional approach
that targets one or the other enzyme or a single molecule (or
combination therapy) that inhibits both PfA-M1 and PfA-
M17. The latter strategy in particular may reduce the likelihood
of parasites being able to rapidly evolve resistance.
Materials and Methods
Purification and Molecular Analysis of Recombinant M17 Leucyl Aminopepti-
dase. A truncated form of PfA-M17 lacking the N-terminal Asn-rich repeat
region was prepared by PCR amplification using the synthesized gene (7)
as a template followed by directional cloning into the Escherichia coli expres-
sion vector pTrcHis2B (Invitrogen). Previous studies have shown that the
N-terminal Asn-rich region is highly variable between species and that its re-
moval does not affect proper protein folding or catalytic activity (7). This con-
struct was used to overexpress the truncated form of PfA-M17 in Rosetta2
BL21 cells grown in AutoInduction Media. Overexpressed cells were lysed in
50 mMHepes pH 8.0; 300 mMNaCl. Hexa-Histidine tagged PfA-M17was pur-
ified using a two-step purification process of Ni-NTA-agarose column fol-
lowed by size exclusion chromatography on a Superdex 200 16∕60 using a
AKTAxpress high throughput chromatography system. Biochemical analysis
indicated that kinetic parameters (kcat, Km, kcat∕Km) of material purified
and used in subsequent crystallisation trials were the same as published (7).
Enzymatic Analysis. Aminopeptidase activity was determined as previously
described (7) by measuring the release of the fluorogenic leaving group,
7-amino-4-methyl-coumarin (NHMec) from the fluorogenic peptide sub-
strates H-Leu-NHMec.
Crystallization and X-ray Data Collection. Purified PfA-M17 enzyme was con-
centrated to ∼13 mg∕mL and crystals grown using the hanging drop vapour
diffusionmethod, with 1∶1 (v/v) ratio of protein to mother liquor (0.5mLwell
volume). The crystals appeared in 40% (v/v) polyethylene glycol 400, 0.1 M
Tris (pH 8.5), 0.2 M Lithium sulphate and 1 mM TCEP. Crystal morphology
were typically highly stacked thin plates (length typically 0.8–1.0 mm) that
generally diffracted to only low-resolution. PfA-M17 Zn2þZn2þ crystals were
obtained by soaking crystals in 1 mM ZnCl2 before data collection. Crystals of
the PfA-M17-Co4 and PfA-M17-bestatin complex were obtained by
cocrystallising in the presence of 1 mM ligand before soaking crystals over-
night in mother liquor containing 1 mM metal chloride (MgCl2-bestatin and
ZnCl2-Co4) and 1 mM ligand. Soaks in the presence of different divalent
cations were undertaken to try and improve crystal morphology and diffrac-
tion data quality. The final crystal for the M17-bestatin structure that data
was collected for was from a MgCl2 soak whereas the M17-Co4 data was
collected from a ZnCl2 soak. Data were collected at 100 K using synchrotron
radiation at the Australian synchrotron micro crystallography beamline 3ID1.
The diffraction data for the ligand-free, ligand-free zinc-soak, bestatin-
bound, and Co4-bound protease were collected to 2.0, 2.4, 2.0, and 2.6 Å
resolution, respectively. Fluorescence scans of each crystal were collected
and indicated the presence of zinc in all crystals (peaks detected at 8.63
and 9.58 against theoretical zinc absorbance of 8.6389, 8.6158, and 9.5720).
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Diffraction images were processed using MOSFLM (26), pointless (27) and
SCALA (27) from the CCP4 suite (28). 5% of each dataset was flagged for cal-
culation of RFree (29) with neither a sigma nor a low-resolution cut-off applied
to the data. A summary of statistics is provided in SI Text Table S1. Subsequent
crystallographic and structural analysis was performed using the CCP4i inter-
face (30) to the CCP4 suite (28), unless stated otherwise.
Structure Determination and Refinement. Structure determination proceeded
using the molecular replacement method and the program MOLREP (31). A
pseudotranslation vector (0.5 Å) was present on the c-axis. A search model
was constructed from the crystal structure of aminopeptidase P from E. coli
(PDB ID 1GYT) (probe identified using the FFAS server (32)). A “poly serine”
model consisting of only C-terminal domain of 1GYT was constructed with
residues other than alanine/glycine residues truncated at Cγ atom. 12 mole-
cules, arranged as 2 hexamers, were present in the asymmetric unit and
packed well within the unit cell. Strong unbiased features were observed
for the N-terminal region of each PfA-M17 monomer in the initial electron
density maps, these data supporting the correctness of themolecular replace-
ment solution was confirmed.
Initial structure refinement and model building proceeded using one mo-
lecule in the asymmetric unit (with the other noncrystallographic symmetry
(NCS)-related molecules generated using NCS operators). Maximum likeli-
hood refinement using REFMAC (33), incorporating translation, liberation
and screw-rotation displacement refinement was carried out, using a bulk
solvent correction (Babinet model with mask). After initial C-α backbone
trace was completed for one chain, NCS restraints were reduced to identical
molecules in each hexamer and retained throughout to improve observation
to parameter ratio. Imposed restraints were guided by manual inspection of
the model and Rfree. Simulated annealing composite omit maps were gener-
ated using Crystallography and NMR System (34) omitting 5 % of the model.
All model building and structural validation was done using Crystallography
Object-Oriented Toolkit (35). Water molecules were added to the model
using ARP/wARP (36) when the Rfree reached 25%. Solvent molecules were
retained only if they had acceptable hydrogen-bonding geometry contacts
of 2.5 to 3.5 Åwith protein atoms or with existing solvent and were in good
2Fo-Fc and Fo-Fc electron density. When restraints were relaxed, no change in
electron density was noted.
Each inhibitor complex was initially solved and refined against the
unbound PfA-M17 structure (protein atoms only) and clearly showed un-
biased features in the active site for both structures. Positive electron density
was apparent in the M17 − BES and M17 − Co4 structure in the position of
the loose metal site 1, creating a dimetal center for the active site.
Pymol was used to produce all structural representations. Hydrogen bonds
(excluding water-mediated bonds), were calculated using Lig_contact and
CONTACT (28). Superpositions were conducted using MUSTANG (17).
CCP4MG was used to produce electrostatic diagrams in (Fig. 3) (37). The
coordinates and structure factors are available from the Protein Data Bank
(3KQX; 3KQZ; 3KR4; 3KR5). Raw data and images are available from TARDIS
(www.tardis.edu.au)(38).
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